ExodusPoint Capital Management’s Outlook Therapeutics OTLK Stock Holding History

ExodusPoint Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,235	Closed	-$60K	–	1909
2024 Q3	$60K	Buy	+11,235	New	+$82.2K	﹤0.01%	1533
2021 Q2	–	Sell	-7,095	Closed	-$319K	–	2681
2021 Q1	$319K	Buy	7,095 +5,215	+277%	+$200K	﹤0.01%	1625
2020 Q4	$49K	Buy	+1,880	New	+$39.3K	﹤0.01%	1873
2020 Q1	–	Sell	-550	Closed	-$6K	–	1493
2019 Q4	$6K	Buy	+550	New	+$12.8K	﹤0.01%	1478

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ExodusPoint Capital Management's OTLK Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 11,235 shares — an estimated $60K sold.

ExodusPoint Capital Management first reported a position in OTLK in Q4 2019 and held it in 4 quarters. The position peaked at $319K in Q1 2021. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

ExodusPoint Capital Management reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 11,235 Outlook Therapeutics shares in Q4 2024, an estimated $60K.
ExodusPoint Capital Management first reported a position in Outlook Therapeutics in Q4 2019 and held it in 4 quarters.
ExodusPoint Capital Management's Outlook Therapeutics position peaked at $319K in Q1 2021.
61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.